Molecular Human Reproduction, Vol. 7, No. 2, 205-210,
February 2001
© 2001 European Society of Human Reproduction and Embryology
Implantation and pregnancy |
Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies
1 Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PL 140, 00290 Helsinki, 2 Department of Pathology, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland and 3 Department of Gene Regulation and Differentiation, Division of Molecular Biotechnology, Braunschweig, Germany
Abstract
Extensive angiogenesis and invasion of the maternal decidua by trophoblasts are essential for the development and function of the placenta. Vascular endothelial growth factors (VEGF), placenta growth factor (PlGF) and their receptors VEGFR-1/Flt-1, VEGFR-2/KDR and VEGFR-3/Flt4 have important roles in vasculogenesis and angiogenesis. We have studied the localization of these proteins by immunohistochemistry and Western blotting in the placenta and of PlGF in maternal serum, and their association with diabetes, pre-eclampsia, fetal growth restriction (FGR) and fetal alcohol syndrome (FAS). VEGFR-1 and VEGFR-3 were detected mainly in the syncytiotrophoblastic layer whereas VEGFR-2 was detected in the vascular endothelial cells of the placenta. VEGFR-1, but not the other receptors, showed increased expression in placental syncytiotrophoblasts from 50% of patients with severe pre-eclampsia and FGR when compared with normal placentas. PlGF was undetectable in 38 of 44 samples of amniotic fluid of mothers with normal and complicated pregnancies. However, maternal serum PlGF concentrations were significantly lower in pre-eclamptic patients and in those with FGR when compared to diabetic women or healthy controls. These results suggest that low maternal serum PlGF and increased placental expression of its receptor VEGFR-1 are associated with pre-eclampsia and FGR.
placental growth factor/placenta/pre-eclampsia/trophoblast/VEGF receptors
Notes
4 To whom correspondence should be addressed at: POB 140, 00029 HUS, Finland. E-mail: erja.halmesmaki{at}hus.fi
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Cindrova-Davies, H.-W. Yung, J. Johns, O. Spasic-Boskovic, S. Korolchuk, E. Jauniaux, G. J. Burton, and D. S. Charnock-Jones Oxidative Stress, Gene Expression, and Protein Changes Induced in the Human Placenta during Labor Am. J. Pathol., October 1, 2007; 171(4): 1168 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Padavala, N. Pope, P. Beker, and I. Crocker An Imbalance Between Vascular Endothelial Growth Factor and its Soluble Receptor in Placental Villous Explants of Intrauterine Growth-Restricted Pregnancies Reproductive Sciences, January 1, 2006; 13(1): 40 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Krysiak, A. Bretschneider, E. Zhong, J. Webb, H. Hopp, S. Verlohren, N. Fuhr, M. Lanowska, A. Nonnenmacher, R. Vetter, et al. Soluble Vascular Endothelial Growth Factor Receptor-1 (sFLT-1) Mediates Downregulation of FLT-1 and Prevents Activated Neutrophils From Women With Preeclampsia From Additional Migration by VEGF Circ. Res., December 9, 2005; 97(12): 1253 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shibata, A. Rajakumar, R. W. Powers, R. W. Larkin, C. Gilmour, L. M. Bodnar, W. R. Crombleholme, R. B. Ness, J. M. Roberts, and C. A. Hubel Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4895 - 4903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Whitehead and L. Lipscomb Patterns of Alcohol Use Before and During Pregnancy and the Risk of Small-for-Gestational-Age Birth Am. J. Epidemiol., October 1, 2003; 158(7): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-y. Liu, Y.-q. Wei, L. Yang, X. Zhao, L. Tian, J.-m. Hou, T. Niu, F. Liu, Y. Jiang, B. Hu, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2 Blood, September 1, 2003; 102(5): 1815 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Torry, D. Mukherjea, J. Arroyo, and R. J. Torry Expression and Function of Placenta Growth Factor: Implications for Abnormal Placentation Reproductive Sciences, May 1, 2003; 10(4): 178 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 U. A. Kayisli, R. Demir, G. Erguler, and A. Arici Vasodilator-stimulated phosphoprotein expression and its cytokine-mediated regulation in vasculogenesis during human placental development Mol. Hum. Reprod., November 1, 2002; 8(11): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Geva, D. G. Ginzinger, C. J. Zaloudek, D. H. Moore, A. Byrne, and R. B. Jaffe Human Placental Vascular Development: Vasculogenic and Angiogenic (Branching and Nonbranching) Transformation Is Regulated by Vascular Endothelial Growth Factor-A, Angiopoietin-1, and Angiopoietin-2 J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4213 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, M.-N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen, and D. J. Hicklin Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis J. Exp. Med., June 17, 2002; 195(12): 1575 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wulff, H. Wilson, S. E. Dickson, S. J. Wiegand, and H. M. Fraser Hemochorial Placentation in the Primate: Expression of Vascular Endothelial Growth Factor, Angiopoietins, and Their Receptors Throughout Pregnancy Biol Reprod, March 1, 2002; 66(3): 802 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lash, A. MacPherson, D. Liu, D. Smith, S. Charnock-Jones, and P. Baker Abnormal fetal growth is not associated with altered chorionic villous expression of vascular endothelial growth factor mRNA Mol. Hum. Reprod., November 1, 2001; 7(11): 1093 - 1098. [Abstract] [Full Text] [PDF]
|
|